Thorsten Fuereder

TL;DR: A randomised, phase 3 study of participants with untreated locally incurable recurrent or metastatic HNSCC done at 200 sites in 37 countries finds that pembrolizumab alone improved overall survival and progression-free survival and cetuximab with chemotherapy improved Overall survival in the total population.

TL;DR: The mTOR pathway is active in about 40% of patients with HCC undergoing OLT, but has no influence of DFS or OS, and no direct correlation was observed between up- and downstream proteins limiting the use of upstream proteins to predict mTOR activity.

TL;DR: Signaling through mTOR is an important link between synovitis and structural damage in inflammatory arthritis and current pharmacologic inhibitors of mTOR could be effective in protecting joints against structural damage.

TL;DR: It is shown that vaccination with an influenza virus strain lacking the viral interferon antagonist NS1 induces statistically significant levels of strain-specific and cross-neutralizing antibodies despite the highly attenuated replication-deficient phenotype.

TL;DR: At the second interim analysis (IA2), P significantly improved OS in the phase 3 study of P or P + chemo (C) vs EXTREME (E) as 1L therapy for R/M HNSCC (NCT02358031).